These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 20881385)

  • 1. Acute heart failure clinical drug development: from planning to proof of activity to phase III.
    Cotter G; Voors AA; Weatherley BD; Pang PS; Teerlink JR; Filippatos G; Ponikowski P; Milo-Cotter O; Dittrich H; Teichman SL; Adams KF; Gheorghiade M; Metra M
    Cardiology; 2010; 116(4):292-301. PubMed ID: 20881385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical development of pharmacologic agents for acute heart failure syndromes: a proposal for a mechanistic translational phase.
    Gheorghiade M; Pang PS; O'Connor CM; Prasad K; McMurray J; Teerlink JR; Fiuzat M; Sabbah H; Komajda M
    Am Heart J; 2011 Feb; 161(2):224-32. PubMed ID: 21315202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The management of acute heart failure.
    Milo-Cotter O; Bettari L; Kleijn L; Bugatti S; Lombardi C; Rund M; Metra M; Voors AA; Cotter G; Kaluski E; Weatherley BD
    Panminerva Med; 2010 Mar; 52(1):53-66. PubMed ID: 20228726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rationale and design of the enoximone clinical trials program.
    Lowes BD; Shakar SF; Metra M; Feldman AM; Eichhorn E; Freytag JW; Gerber MJ; Liard JF; Hartman C; Gorczynski R; Evans G; Linseman JV; Stewart J; Robertson AD; Roecker EB; Demets DL; Bristow MR
    J Card Fail; 2005 Dec; 11(9):659-69. PubMed ID: 16360960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A clinical development paradigm for cancer vaccines and related biologics.
    Hoos A; Parmiani G; Hege K; Sznol M; Loibner H; Eggermont A; Urba W; Blumenstein B; Sacks N; Keilholz U; Nichol G;
    J Immunother; 2007 Jan; 30(1):1-15. PubMed ID: 17198079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anticancer Drug Development: The Way Forward.
    Connors T
    Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rationale and design of the hemodynamic, echocardiographic and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure (HORIZON-HF) trial.
    Blair JE; Macarie C; Ruzyllo W; Bacchieri A; Valentini G; Bianchetti M; Pang PS; Harinstein ME; Sabbah HN; Filippatos GS; Gheorghiade M;
    Am J Ther; 2008; 15(3):231-40. PubMed ID: 18496261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alternative strategies in drug development: clinical pharmacological aspects.
    Kuhlmann J
    Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serelaxin in acute heart failure: Most recent update on clinical and preclinical evidence.
    Ghosh RK; Banerjee K; Tummala R; Ball S; Ravakhah K; Gupta A
    Cardiovasc Ther; 2017 Feb; 35(1):55-63. PubMed ID: 27727514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population.
    Nieminen MS; Brutsaert D; Dickstein K; Drexler H; Follath F; Harjola VP; Hochadel M; Komajda M; Lassus J; Lopez-Sendon JL; Ponikowski P; Tavazzi L; ;
    Eur Heart J; 2006 Nov; 27(22):2725-36. PubMed ID: 17000631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tezosentan in patients with acute heart failure: design of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Study (VERITAS).
    Teerlink JR; McMurray JJ; Bourge RC; Cleland JG; Cotter G; Jondeau G; Krum H; Metra M; O'Connor CM; Parker JD; Torre-Amione G; Van Veldhuisen DJ; Frey A; Rainisio M; Kobrin I;
    Am Heart J; 2005 Jul; 150(1):46-53. PubMed ID: 16084150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early worsening heart failure in patients admitted with acute heart failure--a new outcome measure associated with long-term prognosis?
    Weatherley BD; Milo-Cotter O; Felker GM; Uriel N; Kaluski E; Vered Z; O'Connor CM; Adams KF; Cotter G
    Fundam Clin Pharmacol; 2009 Oct; 23(5):633-9. PubMed ID: 19656213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical evaluation of new therapies for treatment of mucus hypersecretion in respiratory diseases.
    Disse B
    Novartis Found Symp; 2002; 248():254-72; discussion 272-6, 277-82. PubMed ID: 12568499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation.
    During MJ; Kaplitt MG; Stern MB; Eidelberg D
    Hum Gene Ther; 2001 Aug; 12(12):1589-91. PubMed ID: 11529246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Modern therapy of cardiac insufficiency].
    Stojsić D; Jelkić N
    Med Pregl; 1999; 52(3-5):113-24. PubMed ID: 10518395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heart failure therapeutics on the basis of a biased ligand of the angiotensin-2 type 1 receptor. Rationale and design of the BLAST-AHF study (Biased Ligand of the Angiotensin Receptor Study in Acute Heart Failure).
    Felker GM; Butler J; Collins SP; Cotter G; Davison BA; Ezekowitz JA; Filippatos G; Levy PD; Metra M; Ponikowski P; Soergel DG; Teerlink JR; Violin JD; Voors AA; Pang PS
    JACC Heart Fail; 2015 Mar; 3(3):193-201. PubMed ID: 25650371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regarding: Rosenthal DI, Glatstein E. "We've Got a Treatment, but What's the Disease?" The Oncologist 1996;1.
    Lunsford LD; Flickinger JC; Larson D
    Oncologist; 1997; 2(1):59-61. PubMed ID: 10388030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First human chronic experience with cardiac contractility modulation by nonexcitatory electrical currents for treating systolic heart failure: mid-term safety and efficacy results from a multicenter study.
    Pappone C; Augello G; Rosanio S; Vicedomini G; Santinelli V; Romano M; Agricola E; Maggi F; Buchmayr G; Moretti G; Mika Y; Ben-Haim SA; Wolzt M; Stix G; Schmidinger H
    J Cardiovasc Electrophysiol; 2004 Apr; 15(4):418-27. PubMed ID: 15089990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.